- Tous > Medicine Access and Rational Use > Financing
- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > expenditures - health R&D activities
- Mots-clés > health research
- Mots-clés > health research - trends
- Mots-clés > new medicines
- Mots-clés > pharmaceutical research and development (R&D)
- Mots-clés > Public-Private Partnerships (PPPs)
- Mots-clés > research and development - global financing
- Mots-clés > research and innovation
(2006; 102 pages)
As part of its contribution to closing the ‘10/90 gap’, the Global Forum for Health Research conducts studies of the flows of financial resources for health research and the extent to which these do, or do not, address the health needs of the poor and marginalized. Two earlier studies of global resource flows traced the substantial increases that have taken place in investments in health R&D (US$ 85 billion in 1998, rising to almost US$ 106 billion in 2001) and highlighted the mismatch that persists between how research resources are used and the burdens of disease affecting less developed countries.
The ‘bottom line’ of the accounting sheet does not tell the whole story, however. These global totals of research expenditure are composed of many sub-components derived from the public and private sectors in high-income, middle-income and low-income countries. Where exactly does the money come from? How much does each source provide, where does the money go and how well are the allocations aligned with health research priorities at global and local levels? The answers to these questions are not merely of academic interest. The information can be immensely valuable in the identification of gaps that require filling and in supporting evidence-based policies on the magnitude and direction of future health research efforts.
This new volume of Monitoring Financial Flows for Health Research looks behind the global totals and examines several facets of the overall picture, including health research funding by low- and middle-income country governments and the private sector, as well as with the financing of research on some major neglected diseases.
Chapter 3 focuses on basic research to lay the groundwork and discover new, effective drugsand vaccines. Equally important are applied, translational research to turn a discovery into an appropriate drug for human consumption, and development through trials to establish with greater confidence the safety and efficacy of a drug-candidate.